Business Wire India
LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant...
Business Wire India
2024 Award Celebrates Outstanding Research in Cancer Immunology
Winners Discovered Novel Connections Between the Immune System and Cancer
Recipients Each Receive...